Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joy Lee

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Asia Pacific Allergy|November 14, 2019
Continued loss of asthma control following epidemic thunderstorm asthmaChuan T Foo, Ellen Ly Yee, Alan Young, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 16, 2025
Poor diagnostic performance of flow volume loops for detection of inducible laryngeal obstruction/vocal cord dysfunctionLaurence E Ruane, Paul Leong, Garun S Hamilton, et al.
The Journal of Pediatrics|June 16, 2022
Longitudinal Natural History of Pediatric Subjects Affected with Mucopolysaccharidosis IIIBIlyas Okur, Fatih Ezgu, Roberto Giugliani, et al.
Allergology International : Official Journal of the Japanese Society of Allergology|July 1, 2026
Sustained clinical remission and relapse of severe eosinophilic asthma following long-term mepolizumab treatmentRejoy Sabin Thomas, Dennis Thomas, Vanessa M McDonald, et al.
Internal Medicine Journal|September 10, 2021
Patient care standards for primary mitochondrial disease in Australia: an Australian adaptation of the Mitochondrial Medicine Society recommendationsCarolyn M Sue, Shanti Balasubramaniam, Drago Bratkovic, et al.
Allergy|September 23, 2018
The 2016 Melbourne thunderstorm asthma epidemic: Risk factors for severe attacks requiring hospital admissionMark Hew, Joy Lee, Nugroho H Susanto, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|May 27, 2026
A Real-World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe AsthmaDennis Thomas, Vanessa M McDonald, Gijo Thomas, et al.
The European Respiratory Journal|March 7, 2020
Mepolizumab effectiveness and identification of super-responders in severe asthmaErin S Harvey, David Langton, Constance Katelaris, et al.
Respiratory Medicine|September 5, 2025
Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab RegistryErin S Harvey, Yuto Hamada, Sarah A Hiles, et al.
Allergy|August 26, 2023
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patientsDennis Thomas, Vanessa M McDonald, Sean Stevens, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Asia Pacific Allergy|November 14, 2019
Continued loss of asthma control following epidemic thunderstorm asthmaChuan T Foo, Ellen Ly Yee, Alan Young, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 16, 2025
Poor diagnostic performance of flow volume loops for detection of inducible laryngeal obstruction/vocal cord dysfunctionLaurence E Ruane, Paul Leong, Garun S Hamilton, et al.
The Journal of Pediatrics|June 16, 2022
Longitudinal Natural History of Pediatric Subjects Affected with Mucopolysaccharidosis IIIBIlyas Okur, Fatih Ezgu, Roberto Giugliani, et al.
Allergology International : Official Journal of the Japanese Society of Allergology|July 1, 2026
Sustained clinical remission and relapse of severe eosinophilic asthma following long-term mepolizumab treatmentRejoy Sabin Thomas, Dennis Thomas, Vanessa M McDonald, et al.
Internal Medicine Journal|September 10, 2021
Patient care standards for primary mitochondrial disease in Australia: an Australian adaptation of the Mitochondrial Medicine Society recommendationsCarolyn M Sue, Shanti Balasubramaniam, Drago Bratkovic, et al.
Allergy|September 23, 2018
The 2016 Melbourne thunderstorm asthma epidemic: Risk factors for severe attacks requiring hospital admissionMark Hew, Joy Lee, Nugroho H Susanto, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|May 27, 2026
A Real-World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe AsthmaDennis Thomas, Vanessa M McDonald, Gijo Thomas, et al.
The European Respiratory Journal|March 7, 2020
Mepolizumab effectiveness and identification of super-responders in severe asthmaErin S Harvey, David Langton, Constance Katelaris, et al.
Respiratory Medicine|September 5, 2025
Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab RegistryErin S Harvey, Yuto Hamada, Sarah A Hiles, et al.
Allergy|August 26, 2023
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patientsDennis Thomas, Vanessa M McDonald, Sean Stevens, et al.
Pageof 9